Pillstats
Rx only · Tablet, Film Coated, Extended Release · Oral

Paroxetine

Paroxetine Hydrochloride Hemihydrate

6 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US21 NDCs
6 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCN06AB05
RxCUI (US)32937
US makers6 labelers
Packages32
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 9 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.139$0.278$0.417$0.556Dec 2025Apr 2026Jul 2026
$0.433
Latest avg · Jul 22, 2026
-9%
Since Dec 17, 2025
6
Active US suppliers
56%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

1.6K3.2K4.8K6.4K2025 Q12025 Q22025 Q32025 Q42026 Q1
4.5K
Rx · 2026 Q1
193K
Units dispensed
+25%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it6 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Alembic Pharmaceuticals Limitedunknown12SUPPLYING
Cadila Pharmaceuticals Limitedunknown6SUPPLYING
Modavar Pharmaceuticals LLCunknown6SUPPLYING
Chartwell RX, LLCunknown3SUPPLYING
Westminster Pharmaceuticals, LLCunknown3SUPPLYING
Lupin Pharmaceuticals,Inc.unknown2SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Jun 22, 2017
    RECALLRecall (Class III): Paroxetine Extended-Release Tablets USP, 12.5 mg, 30 count bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, In…

    Failed Dissolution Specifications: out of specification observed in dissolution testing at 3 month long term stability study. — Recalling firm: Lupin Pharmaceuticals Inc. — Nationwide in the USA